The environmental decision issued by the Mayor of Wrocław marks a key milestone in the implementation of the most important investment in the history of the publicly listed company – the construction of a large-scale manufacturing facility for biological medicines for companion animals. The decision precedes Bioceltix’s application for a building permit for what is set to become the largest pharmaceutical facility of its kind in the world.
The large-scale plant will provide the veterinary biotech company with the target production capacity for medicines based on its proprietary ALLO-BCLX technology, designed to combat the most common diseases in dogs and horses, and in the future also in cats. Construction works are scheduled for completion in the first quarter of 2027.
“The environmental decision was the final formal requirement needed to submit our application for a building permit. We have already announced the first tenders and, together with contracted subcontractors, are progressing through subsequent stages of the project. We are at a very dynamic and exciting point in Bioceltix’s development,” emphasizes Paweł Wielgus, Member of the Management Board.
Multiplying Production Capacity
The new facility will enable the production of target volumes of Bioceltix medicinal products intended for international sales. It will allow for the commercialization of the Wrocław-based company’s flagship therapies: two for dogs – one for osteoarthritis and one for atopic dermatitis – and a third for horses suffering from lameness, following their marketing authorization in accordance with European Union procedures.
Clinical trials of the innovative products, which leverage the immunomodulatory properties of stem cells, have demonstrated significant therapeutic efficacy while confirming the absence of serious adverse effects. Registration procedures with the European Medicines Agency are already underway, and the company expects its first recommendation – concerning BCX-CM-J for canine osteoarthritis – by the end of this year. This represents an opportunity for Bioceltix to become the first company in the world to receive marketing authorization for a medicinal product based on canine stem cells.
“Our products are already being manufactured at our current low-scale facility operating under pharmaceutical standards, ensuring supply for R&D, clinical trials, and future pilot sales. However, we must prepare to scale up production, and that requires a new manufacturing plant,” explains Paweł Wielgus.
The facility will support international markets. It will encompass the complete medicinal product manufacturing process, from sourcing donor material, through stem cell expansion and packaging, to product storage, along with quality control, analytical, and research and development infrastructure.
“Our analyses indicate that currently no entity worldwide is capable of producing, for therapeutic purposes, the volume of animal stem cells that we plan to obtain from the new facility. The investment outlays required to launch it are, of course, substantial, but considering the business potential behind it, we have no doubts about this project. The timing is very favorable for veterinary biotechnology. All signs suggest that a biological medicine will be the first product in the history of veterinary medicine to achieve annual sales exceeding USD 1 billion. We also benefit from the changing attitude of pet owners, who increasingly treat animals as full-fledged family members,” says Paweł Wielgus.
A Strategic Project
The company estimates that achieving large-scale pharmaceutical manufacturing capacity will require approximately EUR 9 million in the initial phase of the plant’s operations. The construction of the facility is being financed from funds raised through a share issuance. Part of the expenditure is also expected to be covered by a conditional grant from the Polish Agency for Enterprise Development (PARP) in the amount of PLN 17.5 million.
As emphasized by the company’s management board, a solid balance sheet position, constructive dialogue with the EMA, and consistent execution of subsequent investment stages provide Bioceltix with strong comfort in discussions with partners and a favorable negotiating position. This brings the Wrocław-based company closer to launching commercial production of advanced veterinary biological therapies – from Wrocław to markets worldwide.